[Effect of puerarin preconditioning on cytokine levels in patients undergoing cardiopulmonary bypass in perioperative period].
OBJECTIVE
To study the effect and acting mechanism of puerarin preconditioning (PP) on blood level of cytokines in patients undergoing cardiopulmonary bypass (CPB) in perioperative period.


METHODS
Forty patients with heart diseases scheduled to take surgical operation were randomized into the control group and the PP group equally. They were treated with the same program, excepting that 0.6 g of puerarin was given to the PP group by adding in 5% glucose solution 250 mL for intravenous dripping every day for one week before operation, but to the control group, normal saline was given instead. The levels of tumor necrosis factor-alpha (TNF-alpha), interleukin 6, 8 and 10 (IL-6, IL-8, IL-10) in arterial blood were measured at 5 time points in the process of CPB, namely, anesthetic induction (T1), 10 min after the clamp of the ascending aorta (T2), 10 min, 2 h and 12 h after the Clamped aorta is unclamped (T3, T4 and T5).


RESULTS
All the above-mentioned indexes (TNF-alpha, IL-6, IL-8 and IL-10) gradually increased after beginning CPB, reached the peak at T4, then lowered gradually but still presented the higher levels at T5 than those at T1 (P < 0.05). Comparison between the two groups showed that levels of TNF-alpha, IL-6 and IL-8 were significantly lower (P < 0.05 or P < 0.01) and level of IL-10 was higher in the PP group than those in the control group respectively at all the time points (P < 0.01).


CONCLUSIONS
Injecting puerarin before CPB could effectively suppress the pro-inflammatory cytokines like TNF-alpha, IL-6 and IL-8; and enhance the expression of anti-inflammatory cytokines like IL-10, thus to alleviate the inflammatory reaction induced by CPB.
Jiang
Xiao-xiao
XX
Departmemt of Cardiovascular Surgery, Second Affiliated Hospital of Nanchang University, Nanchang. jxx-smart@hotmail.com
Li
Yong
Y
Wu
Yong-bin
YB
D000293:Adolescent; D000328:Adult; D002315:Cardiopulmonary Bypass; D005260:Female; D006331:Heart Diseases / Q000097:blood* / Q000601:surgery*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D019194:Ischemic Preconditioning / Q000379:methods*; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D059035:Perioperative Period; D011184:Postoperative Period; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D055815:Young Adult
D015850:Interleukin-6; D016209:Interleukin-8; D007529:Isoflavones; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; C033607:puerarin